New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
10:06 EDTAVGO, MNDL, MCO, VRX, HYGS, CFX, ARP, ORCL, EPE, CRZO, ATLS, MHFI, CXP, BBG, SYRG, ISSIOn The Fly: Analyst Initiation Summary
Atlas Energy (ATLS) initiated with a Buy at Deutsche Bank... Atlas Resource Partners (ARP) initiated with a Hold at Deutsche Bank... Bill Barrett (BBG) initiated with a Neutral at Mizuho... Carrizo Oil & Gas (CRZO) initiated with a Buy at Mizuho... Colfax (CFX) initiated with a Neutral at Longbow... Columbia Property Trust (CXP) initiated with a Market Perform at JMP Securities... EP Energy (EPE) initiated with a Neutral at Mizuho... Integrated Silicon (ISSI) initiated with a Buy at B. Riley... McGraw Hill Financial (MHFI) initiated with a Buy at Janney Capital... Oracle (ORCL) initiated with a Buy at Cantor... Synergy Resources (SYRG) initiated with an Outperform at Imperial Capital... Valeant (VRX) initiated with a Buy at Cantor... Mandalay Digital (MNDL) initiated with a Buy at Craig-Hallum... Hydrogenics (HYGS) initiated with a Buy at Ascendiant... Moody's (MCO) initiated with a Neutral at Janney Capital... Avago (AVGO) initiated with an Outperform at Pacific Crest.
News For ATLS;ARP;BBG;CRZO;CFX;CXP;EPE;ISSI;MHFI;ORCL;SYRG;VRX;MNDL;HYGS;MCO;AVGO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
June 17, 2015
16:35 EDTORCLOracle drops over 5% after reporting Q4 financial results
Subscribe for More Information
16:13 EDTORCLOracle: Q4 SaaS and PaaS revenues grew at a 34% constant currency rate
Subscribe for More Information
16:12 EDTORCLCrossroads Systems updates on patent litigation after Markman hearing
Subscribe for More Information
16:10 EDTORCLOracle sees $1.5B-$2B new Saas, Paas business in fiscal year
Subscribe for More Information
16:02 EDTORCLOracle reports Q4 EPS 78c, consensus 87c
Subscribe for More Information
15:27 EDTISSIGlass Lewis recommends Integrated Silicon holders approve Uphill acquisition
Integrated Silicon Solution announced that the proxy advisory firm Glass Lewis has recommended that ISSI stockholders vote FOR the proposed acquisition of ISSI by Uphill Investment Co. and related matters at the Special Meeting of Stockholders to be held on June 19. The merger agreement between ISSI and Uphill dated as of March 12, as previously amended, provides for consideration of $21.00 per share in cash.
15:16 EDTORCLNotable companies reporting after market close
Subscribe for More Information
15:16 EDTORCLOptions with increasing volume
Subscribe for More Information
14:46 EDTORCLOracle June 45 straddle priced for 4.1% movement into Q4
Subscribe for More Information
14:42 EDTORCLOption volume leaders
Subscribe for More Information
13:50 EDTORCLOracle technical comments before earnings
Subscribe for More Information
13:08 EDTORCLEarnings Watch: Analysts expect cloud to help Oracle beat 'modest' expectations
Subscribe for More Information
11:41 EDTVRXSynergy an 'attractive takeout target' after data, says Cantor
Subscribe for More Information
10:44 EDTVRXSynergy a potential takeover target after constipation drug data
The shares of Synergy Pharmaceuticals (SGYP) are rallying after the company announced that its chronic constipation treatment had met its primary endpoint in a Phase 3 clinical trial. Research firm Canaccord has previously identified Synergy as a potential takeover target and a Bloomberg report said the company had hired advisers to explor a potential sale. WHAT'S NEW: Synergy reported this morning that the 3 mg and 6 mg versions of its anti-constipation drug, plecanatide, had met their primary endpoint in a Phase III trial. Specifically, a statistically significant percentage of patients taking both versions of the drugs responded favorably, based on criteria that the FDA uses to determine approval of chronic constipation treatments, the company stated. Plecanatide was safe and well tolerated at both dose, and the results were positive, the company reported. "These results strengthen our belief that plecanatide has the potential to not only effectively treat constipation but with a durability and tolerability profile that is ideal for chronic use," said Synergy CEO Gary Jacob. "We look forward to the results of our second pivotal trial in the coming weeks," he added. WHAT'S NOTABLE: In a note to investors on May 22, Canaccord analyst Corey Davis initiated coverage of Synergy with a Buy rating. There is "a high likelihood" that data from the company's four Phase III trials due to be conducted over the next year will be positive and the company would be an attractive takeover target if its Phase III data is positive, Jacobs wrote. The analyst placed an $11 price target on the shares. Meanwhile, in March, Bloomberg reported that Synergy was talking to advisers about potentially selling the company after its competitor, Salix Pharmaceuticals, had agreed to be acquired by Valeant Pharmaceuticals (VRX). After the company reported the trial results today, its CEO told Bloomberg that "all options are on the table." IRONWOOD: The shares of Ironwood (IRWD), whose Linzess drug also treats chronic constipation, are falling today following Synergy's data readout. Canaccord's Davis had said that the diarrhea rate of patients taking Synergy's plecanatide had to come in at 10% or lower for the drug to achieve "best differentiation" versus Linzess. Patients taking the 3 mg dose of plecanatide had a diarrhea rate of 5.5%, while 5.9% of those taking the 6 mg dose experienced diarrhea, Synergy reported. Linzess is co-marketed by Ironwood and Forest Pharmaceuticals, a unit of Allergan (AGN). PRICE ACTION: In morning trading, Synergy surged 45% to $6.74, while Ironwood slid fractionally to $12.16.
10:00 EDTEPEOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:17 EDTEPEOn The Fly: Pre-market Movers
Subscribe for More Information
08:06 EDTISSIIntegrated Silicon announces ISS recommends in favor of Uphill transaction
Integrated Silicon Solution announced that the proxy advisory firm ISS has recommended that ISSI stockholders vote FOR the proposed acquisition of ISSI by Uphill Investment and related matters at the Special Meeting of Stockholders to be held on June 19, 2015. The merger agreement between ISSI and Uphill dated as of March 12, 2015, as previously amended, provides for consideration of $21.00 per share in cash. The ISSI board recommends that ISSI stockholders vote FOR the adoption of the merger agreement with Uphill.
06:44 EDTEPEEP Energy downgraded to Sell from Neutral at Citi
Subscribe for More Information
June 16, 2015
11:08 EDTVRXValeant in advanced discussions to acquire Amoun, Bloomberg reports
Subscribe for More Information
10:06 EDTCFXHigh option volume stocks
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use